UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 6, 2006
Lifeline Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Colorado
|
|
000-30489
|
|
84-1097796 |
|
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.) |
6400 South Fiddler’s Green Circle, Suite 1970, Englewood, CO 80111
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (720) 488-1711
6400 South Fiddler’s Green Circle, Suite 1750, Englewood, CO 80111
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 7.01 Regulation FD Disclosure
On February 6, 2006, Lifeline Therapeutics, Inc. (the “Company”) issued a press release
entitled “Lifeline Therapeutics, Inc. Files Amendment No. 1 to Form SB-2.” The press release is
attached as Exhibit 99.1 hereto.
On February 7, 2006, the Company issued a press release entitled “Dr. Larry Gold Joins
Lifeline Therapeutics, Inc. Scientific Advisory Board.” The press release is attached as Exhibit
99.2 hereto.
Item 9.01 Exhibits
99.1 Press Release, dated February 6, 2006, entitled “Lifeline Therapeutics, Inc. Files
Amendment No. 1 to Form SB-2.”
99.2 Press Release, dated February 7, 2006, entitled “Dr. Larry Gold Joins Lifeline
Therapeutics, Inc. Scientific Advisory Board.”
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
Date: February 7, 2006
| |
|
|
|
|
| |
LIFELINE THERAPEUTICS, INC.
|
|
| |
By: |
/s/ Stephen K. Onody
|
|
| |
|
Stephen K. Onody |
|
| |
|
Chief Executive Officer |
|
| |